Printer Friendly

OSTEOTECH'S POLYACTIVE MEMBRANE REPORTED EFFECTIVE IN REDUCING SPINAL SCAR FORMATION

 SHREWSBURY, N.J., July 14 /PRNewswire/ -- A research award was presented to Thomas Whitecloud, M.D., chairman, Department of Orthopaedics, and Stephen Cook, Ph.D., director of Orthopaedic Research, Tulane University, for data presented on Osteotech's Polyactive(TM) polymer membrane at the June meeting of the International Society for the Study of the Lumbar Spine held in Marseilles, France. Ann Prewett, Ph.D., of Osteotech also collaborated on the study.
 In the study entitled "Reduction in Perineural Scar Formation Following Laminectomy using Polyactive Membrane Sheets" the degradable polymer barrier membrane was placed onto the dure covering the spinal cord following a laminectomy procedure in dogs. The membrane acted as a physical barrier to prevent the ingrowth of scar tissue around the spinal cord and nerve roots. If no barrier is used and scar tissue is allowed to form, it can lead to nerve entrapment, recurrent pain and the phenomenon known as "Failed Back Syndrome."
 In 1992 there were over 300,000 laminectomy procedures performed worldwide. The results of this study indicate that the Polyactive barrier membrane may be a reliable and effective means of reducing perineural scar formation following laminectomy. Further preclinical and clinical investigation must be completed prior to submission for regulatory review and commercial introduction.
 "This landmark research study and research in progress with the Polyactive membrane in spinal surgical procedures could lead to a new generation of biomaterial products with unique applications," stated Patrick A. McBrayer, Osteotech president and chief executive officer. "The spine market is very important to Osteotech. Allograft tissue processed by Osteotech is frequently used to augment spinal surgical procedures. Further, as previously announced, the company has entered into an agreement with Heinrich C. Ulrich KG, a German manufacturer of surgical instruments, for the exclusive U.S. marketing rights of all its devices and instruments for spinal surgery. Our dedicated sales force in the United States is well positioned to represent these products and future developments to the Orthopaedic and Neurologic surgeons."
 Through its European subsidiary HC/CAM Implants in Leiden, The Netherlands, Osteotech is developing the Polyactive polymer technology for numerous medical applications in addition to spine surgery.
 Osteotech, Inc. (NASDAQ-NMS: OSTE), headquartered in Shrewsbury, N.J., is a leading processor of human bone and bone connective tissue for transplantation and an innovator in the development and marketing of biologic, biomaterial and implant products for musculoskeletal surgery.
 -0- 7/14/93
 /CONTACT: Michael J. Jeffries of Osteotech, 908-542-2800/
 (OSTE)


CO: Osteotech, Inc. ST: New Jersey IN: MTC SU:

MP-LG -- NY017 -- 1251 07/14/93 09:26 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1993
Words:424
Previous Article:FIRST CHICAGO REPORTS NET INCOME OF $169 MILLION
Next Article:ZIONS FIRST NATIONAL BANK RECEIVES OCC APPROVAL TO PROCEED WITH DISCOUNT CORP. TRANSACTION
Topics:


Related Articles
OSTEOTECH RECEIVES U.S. PATENT FOR A UNIQUE COATING FOR IMPLANTS
OSTEOTECH EXPANDS MARKETING PROGRAM AND IS AWARDED GRAFTON PROCESSED BONE GEL PATENT
OSTEOTECH RECEIVES PATENT ON ARTIFICIAL SKIN
OSTEOTECH'S POLYACTIVE POLYMER PRESENTED AT INTERNATIONAL BIOMATERIALS MEETING
GLIATECH'S ADCON-L EFFICACIOUS IN PRECLINICAL TESTING; STUDY PUBLISHED IN JOURNAL OF NEUROSURGERY
OSTEOTECH AWARDED GRANT BY DUTCH GOVERNMENT FOR RESEARCH ON POLYACTIVE
OSTEOTECH REPORTS RECORD NINE MONTHS AND THIRD QUARTER REVENUES AND EARNINGS
DR. POSER TO DEPART OSTEOTECH
OSTEOTECH REPORTS 1994 REVENUE INCREASED 28.5% TO $24.6 MILLION; NET INCOME INCREASES TO $1.7 MILLION
OSTEOTECH, INC. ANNOUNCES AMERICAN RED CROSS TO DISTRIBUTE GRAFTON DEMINERALIZED BONE MATRIX AND INTENDS TO RENEW LONG-TERM PROCESSING AGREEMENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters